Found 667 clinical trials
A Study to Investigate the Pharmacokinetics Efficacy and Safety of INM005 in Patients With COVID-19.
This study aims to analyze the efficacy and safety of passive immunotherapy by administering an equine hyperimmune serum (INM005) against the SARS-CoV2 RBD to Covid19 patients. Improvement of the clinical course 28 days after the start of treatment will be evaluated.
- 0 views
- 16 Feb, 2024
- 6 locations
Tofacitinib for Treatment of Moderate COVID-19
The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-65 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation.
- 0 views
- 05 Aug, 2020
Convalescent Plasma for the Treatment of COVID-19
This protocol provides access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.
- 0 views
- 16 Feb, 2024
- 1 location
Extracorporeal Blood Purification as a Treatment Modality for COVID-19
Several studies have suggested a potential clinical benefit of controlling hyper inflammation triggered by SARS-CoV-2/COVID-19. Blood purification, the removal of excessive proinflammatory mediators may control disease progression and support clinical recovery.
- 0 views
- 16 Feb, 2024
- 1 location
Hyperimmune Plasma in Patients With COVID-19 Severe Infection
To date, there are not proven etiological therapies for SARS-CoV-2 infection, the agent responsible for the disease called Covid-19. Among those subjected to clinical studies during the current epidemic in China, hyperimmune plasma appears to be one of the most rational and promising.
- 0 views
- 16 Feb, 2024
- 6 locations
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding …
- 0 views
- 16 Feb, 2024
- 1 location
tVNS in Long COVID-19
A prior open label study has shown that transcutaneous vagus nerve stimulation [tVNS] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS).
- 0 views
- 05 May, 2025
- 2 locations
Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group.
- 0 views
- 16 Feb, 2024
- 1 location
To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI
Research based on some plants is more than centuries old and its main therapeutic objective is to stimulate the self-healing power of the body. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy.
- 0 views
- 08 Jul, 2021
Provider Burnout During COVID-19
Since the novel coronavirus, SARS-CoV-2, was first reported in the Hubei province of China in December 2019, the US has become an epicenter for the pandemic, accounting for more than 220,000 cases and 4,800 deaths (CDC).
- 0 views
- 16 Feb, 2024
- 1 location